Nutra Pharma has completed the process of moving all of their inventory of Nyloxin® to their Plantation, Florida facility to begin in-house fulfillment.
September 11, 2013 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin®, into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
“The Distribution and fulfillment of Nyloxin has been a large cost burden over the last 2 years,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. “By bringing the product in-house, we will be saving time on shipments as well as improve our margins by more than 10%," he continued. "We are completing the process this month of moving over 43 pallets of the Nyloxin product to our existing facility in Plantation, Florida providing saleable goods at retail as well as wholesale prices to our customers and Distributors," concluded Mr. Deitsch.
Nyloxin® is a homeopathic drug that utilizes proteins from cobra venom to relieve pain and inflammation. An analgesic that began gaining U.S. attention in 1936, cobra venom’s effects in minute doses have been shown by researchers to be superior to that of morphine, a highly addictive opiate. The product is available in an easy-to-use oral spray for treating: lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, as well as a topical gel for treating: repetitive stress, arthritis and joint pain. Nyloxin® is also available in Extra Strength formulations.
Additional benefits to Nyloxin® include:
• All Natural
The Company recently announced the delivery of the first order of Nyloxin® to their newest Distributor, New Vitality. For the past 16 years New Vitality (www.newvitality.com) has marketed and sold vitamins, health supplements, and personal care products. Customers learn about their products from advertisements which use celebrities, sport athletes and doctors to promote them on over 2000 radio and television stations nationwide.
About Nutra Pharma Corp
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com and www.Nyloxin.net
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The in-house fulfillment of Nyloxin should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.